Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Lonza and Sartorius Modify Relationship for Supply of Cell Culture Media

By Lonza Group Ltd | November 19, 2018

Lonza and Sartorius Stedim Biotech (Sartorius) have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave Sartorius exclusive sales and marketing rights for certain media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes. Lonza retained sales for research-based products, among others.

Under agreements signed, Sartorius will continue to offer current and future Lonza media and buffers on a non-exclusive basis as part of its extensive portfolio of products for cell-based development and manufacturing. Lonza Pharma & Biotech resumes sales and marketing of all its media products for both manufacturing and research. Customers of both companies will continue to be able to source media products for their specific needs.

“As new generations of complex biologics move toward commercial production, media is no longer viewed as a consumable but as a critical part of the package we offer customers developing next-generation therapies, so we are investing accordingly in this area,” said Marc Funk, COO Lonza Pharma & Biotech.

Both companies also have entered into a long-term agreement for supply of equipment and consumables. Under the new agreement, Sartorius will be a preferred supplier for specific Lonza projects.

“Our collaboration over the past years has greatly benefited our customers and both companies. The adapted agreement now reflects the dynamics of this rapidly evolving market, providing additional strategic flexibility for both partners,” commented Reinhard Vogt, member of Sartorius Stedim Biotech’s executive committee.

Lonza is currently investing in its media business and will open a new R&D facility in Rockville, MD by the end of 2018. Supporting the nearby Walkersville, MD site, the new R&D center will drive innovation in media formulation. As biologic-based medicines—including next-generation antibody-based therapeutics and cell and gene therapies—become increasingly complex, media formulations need to be tailored to specific processes.

(Source and Photo: Lonza Group Ltd.)

Related Articles Read More >

coronavirus COVID-19 Pfizer
7 core strategies in Biden’s battle against COVID-19
Biden’s COVID-19 response will make manufacturers busy
Catalent
Catalent to acquire Acorda’s manufacturing and packaging operations 
Halix
Halix to help make AstraZeneca’s COVID-19 vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards